Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023
05 sept. 2023 08h00 HE
|
Cingulate Inc.
KANSAS CITY, Kan., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Bloomberg Philanthropies and the Aspen Institute Announce Bloomberg CityLab 2023 in Washington, D.C.
28 août 2023 09h00 HE
|
The Aspen Institute
New York, NY and Washington, D.C., Aug. 28, 2023 (GLOBE NEWSWIRE) -- The tenth Bloomberg CityLab, the preeminent global cities summit organized by Bloomberg Philanthropies in partnership with the...
Tiziana Life Sciences Announces Live Bloomberg TV Interview of Renowned Scientist Dr. Howard L. Weiner to Discuss FDA IND Clearance for Intranasal Foralumab in Alzheimer's Disease
17 août 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD
11 juil. 2023 08h00 HE
|
Cingulate Inc.
KANSAS CITY, Kan., July 11, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August
29 juin 2023 08h00 HE
|
Cingulate Inc.
KANSAS CITY, Kan., June 29, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD
08 juin 2023 07h00 HE
|
Cingulate Inc.
Study Assessed Onset and Duration of CTx-1301 in Adults, Results Expected 3Q 2023 Pivotal Phase 3 Trials in Pediatric/Adolescent Patients on Schedule for 3Q 2023 Initiation KANSAS CITY, Kan., June ...
Cingulate to Present at 13th Annual LD Micro Invitational
25 mai 2023 15h55 HE
|
Cingulate Inc.
KANSAS CITY, Kan., May 25, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Mobiquity Technologies Launches ElecTech, an AI Powered Programmatic Advertising Solution for Political Campaigns
18 mai 2023 08h00 HE
|
Mobiquity Technologies, Inc.
NEW YORK, May 18, 2023 (GLOBE NEWSWIRE) -- Mobiquity Technologies, Inc. (NASDAQ: MOBQ) (the “Company”), a leading provider of next-generation data intelligence and advertising technology solutions,...
Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update
10 mai 2023 16h15 HE
|
Cingulate Inc.
Additional $3 Million of Financing Proprietary PTR™ Manufacturing Processes Successfully Transferred to Societal CDMO Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301 KANSAS...
Cingulate Announces Successful Transfer of CTx-1301 (dexmethylphenidate) Proprietary PTR™ Manufacturing Processes to Societal CDMO
03 mai 2023 06h45 HE
|
Cingulate Inc.
KANSAS CITY, Kan., May 03, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...